title: Reply to "Risperidone-induced obsessive-compulsive symptoms: serotonin-dopamine imbalance?".
authors.forename: Basil
authors.initials: B
authors.lastname: Alevizos
authors.forename: Lefteris
authors.initials: L
authors.lastname: Lykouras
authors.forename: Iannis M
authors.initials: IM
authors.lastname: Zervas
authors.forename: George N
authors.initials: GN
authors.lastname: Christodoulou
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001921:Brain / Q000187:drug effects*; D004298:Dopamine / Q000378:metabolism*; D065127:Dopamine D2 Receptor Antagonists; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D008134:Long-Term Care; D009771:Obsessive-Compulsive Disorder / Q000139:chemically induced*; D012307:Risk Factors; D018967:Risperidone / Q000009:adverse effects* / Q000627:therapeutic use; D012701:Serotonin / Q000378:metabolism*; D058830:Serotonin 5-HT2 Receptor Antagonists
chemical_list: D014150:Antipsychotic Agents; D065127:Dopamine D2 Receptor Antagonists; D058830:Serotonin 5-HT2 Receptor Antagonists; D012701:Serotonin; D018967:Risperidone; D004298:Dopamine